163 related articles for article (PubMed ID: 31801939)
1. Characterization of the role of TMEM45A in cancer cell sensitivity to cisplatin.
Schmit K; Chen JW; Ayama-Canden S; Fransolet M; Finet L; Demazy C; D'Hondt L; Graux C; Michiels C
Cell Death Dis; 2019 Dec; 10(12):919. PubMed ID: 31801939
[TBL] [Abstract][Full Text] [Related]
2. TMEM45A Affects Proliferation, Apoptosis, Epithelial-Mesenchymal Transition, Migration, Invasion and Cisplatin Resistance of HPV-Positive Cervical Cancer Cell Lines.
Liu Y; Liu L; Mou ZX
Biochem Genet; 2022 Feb; 60(1):173-190. PubMed ID: 34143331
[TBL] [Abstract][Full Text] [Related]
3. TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells.
Flamant L; Roegiers E; Pierre M; Hayez A; Sterpin C; De Backer O; Arnould T; Poumay Y; Michiels C
BMC Cancer; 2012 Sep; 12():391. PubMed ID: 22954140
[TBL] [Abstract][Full Text] [Related]
4. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
[TBL] [Abstract][Full Text] [Related]
5. Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells.
Wang Z; Liu S; Ding K; Ding S; Li C; Lu J; Gao D; Zhang T; Bi D
Tumour Biol; 2016 Nov; 37(11):15133-15143. PubMed ID: 27677286
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of CD44 sensitizes cisplatin-resistance and affects Wnt/β-catenin signaling in HNSCC cells.
Roy S; Kar M; Roy S; Padhi S; Kumar A; Thakur S; Akhter Y; Gatto G; Banerjee B
Int J Biol Macromol; 2020 Apr; 149():501-512. PubMed ID: 31953176
[TBL] [Abstract][Full Text] [Related]
7. BCAT1 overexpression regulates proliferation and c‑Myc/GLUT1 signaling in head and neck squamous cell carcinoma.
Wang H; Wang F; Ouyang W; Jiang X; Wang Y
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760210
[TBL] [Abstract][Full Text] [Related]
8. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma.
Robinson AM; Rathore R; Redlich NJ; Adkins DR; VanArsdale T; Van Tine BA; Michel LS
Cell Death Dis; 2019 Nov; 10(11):867. PubMed ID: 31727874
[TBL] [Abstract][Full Text] [Related]
10. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
[No Abstract] [Full Text] [Related]
11. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
[TBL] [Abstract][Full Text] [Related]
12. LAMB3 is associated with disease progression and cisplatin cytotoxic sensitivity in head and neck squamous cell carcinoma.
Liu L; Jung SN; Oh C; Lee K; Won HR; Chang JW; Kim JM; Koo BS
Eur J Surg Oncol; 2019 Mar; 45(3):359-365. PubMed ID: 30414703
[TBL] [Abstract][Full Text] [Related]
13. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
[TBL] [Abstract][Full Text] [Related]
14. ATR inhibition sensitizes HPV
Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment with cisplatin and the tankyrase inhibitor XAV-939 increases cytotoxicity, abrogates cancer-stem-like cell phenotype and increases chemosensitivity of head-and-neck squamous-cell carcinoma cells.
Roy S; Roy S; Kar M; Chakraborty A; Kumar A; Delogu F; Asthana S; Hande MP; Banerjee B
Mutat Res Genet Toxicol Environ Mutagen; 2019 Oct; 846():503084. PubMed ID: 31585633
[TBL] [Abstract][Full Text] [Related]
16. Increased FOXM1 Expression by Cisplatin Inhibits Paclitaxel-Related Apoptosis in Cisplatin-Resistant Human Oral Squamous Cell Carcinoma (OSCC) Cell Lines.
Choi HS; Kim YK; Hwang KG; Yun PY
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255409
[TBL] [Abstract][Full Text] [Related]
17. p38 Mitogen-activated protein kinase modulates cisplatin resistance in Head and Neck Squamous Cell Carcinoma cells.
Roy S; Roy S; Anuja K; Thakur S; Akhter Y; Padhi S; Banerjee B
Arch Oral Biol; 2021 Feb; 122():104981. PubMed ID: 33302041
[TBL] [Abstract][Full Text] [Related]
18. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
[TBL] [Abstract][Full Text] [Related]
19. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.
Liu S; Wang Y; Han Y; Xia W; Zhang L; Xu S; Ju H; Zhang X; Ren G; Liu L; Ye W; Zhang Z; Hu J
Theranostics; 2020; 10(23):10589-10605. PubMed ID: 32929368
[No Abstract] [Full Text] [Related]
20. High Notch1 expression affects chemosensitivity of head and neck squamous cell carcinoma to paclitaxel and cisplatin treatment.
Zhang Z; Zhou Z; Zhang M; Gross N; Gong L; Zhang S; Lei D; Zeng Q; Luo X; Li G; Li X
Biomed Pharmacother; 2019 Oct; 118():109306. PubMed ID: 31545250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]